series-b
Stage
About
Sudo Biosciences is a clinical-stage neuro-immunology biotechnology company developing brain-penetrant and allosteric small-molecule TYK2 inhibitors for neurological and immune-mediated inflammatory diseases such as multiple sclerosis and psoriasis.
Explore Sudo Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.